Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 211-218 , June 2003

Management of treatment-related osteoporosis in men with prostate cancer

  • Matthew R Smith

      Affiliations

    • Corresponding Author InformationCorrespondence to: Matthew R. Smith, MD, PhD, Haematology-Oncology Division, Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114, USA, Tel.: 1-617-724-5257; Fax: 1-617-726-4899

References 

  1. Siddiqui NA, Shetty KR, Duthie EH. Osteoporosis in older men: discovering when and how to treat it. Geriatrics. 1999;54:20–22 27–28, 30 pp.
  2. Seeman E. The structural basis of bone fragility in men. Bone. 1999;25:143–147
  3. Orwoll ES. Osteoporosis in men. Endocrinol. Metab. Clin. North Am. 1998;27:349–367
  4. Bilezikian JP. Osteoporosis in men. J. Clin. Endocrinol. Metab. 1999;84:3431–3434
  5. Robson M, Dawson N. How is androgen-dependent metastatic prostate cancer best treated?. Hematol. Oncol. Clin. North Am. 1996;10:727–747
  6. Moul JW. Contemporary hormonal management of advanced prostate cancer. Oncology (Hunting). 1998;12:499–505 discussion 506–508
  7. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 1984; 311: 1281–1286
  8. Smith MR, McGovern FJ, Zietman AL, et al.  Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N. Engl. J. Med. 2001;345:948–955
  9. Agency for Health Care Policy and Research. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Summary, evidence report/technology assessment: No. 4. Available from: http://ahrq.gov/clinic/prossumm.htm, 1999
  10. Cummings SR, Black DM, Nevitt MC, et al.  Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group [see comments]. JAMA. 1990;263:665–668
  11. Cummings SR, Black DM, Nevitt MC, et al.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group [see comments]. Lancet. 1993;341:72–75
  12. Gardsell P, Johnell O, Nilsson BE. The predictive value of forearm bone mineral content measurements in men. Bone. 1990;11:229–232
  13. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 1991;115:837–842
  14. Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J. Bone Miner. Res. 1994;9:1137–1141
  15. Eastell R. Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1998;338:736–746
  16. Selby PL, Davies M, Adams JE. Do men and women fracture bones at similar bone densities?. Osteoporos. Int. 2000;11:153–157
  17. Grampp S, Jergas M, Gluer CC, Lang P, Brastow P, Genant HK. Radiologic diagnosis of osteoporosis. Current methods and perspectives. Radiol. Clin. North Am. 1993;31:1133–1145
  18. Schutte HE, Park WM. The diagnostic value of bone scintigraphy in patients with low back pain. Skeletal. Radiol. 1983;10:1–4
  19. Daniell HW. Osteoporosis after orchiectomy for prostate cancer [see comments]. J. Urol. 1997;157:439–444
  20. Townsend MF, Sanders WH, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997;79:545–550
  21. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer [in process citation]. BJU Int. 2000;86:449–452
  22. Oefelein MG, Ricchuiti V, Conrad W, et al.  Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J. Urol. 2001;166:1724–1728
  23. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with oestrogens. Calcif Tissue Int. 1995;57:97–99
  24. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. 1999;161:1219–1222
  25. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol. 2000;163:181–186
  26. Berruti A, Dogliotti L, Terrone C, et al.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. Urol. 2002;167:2361–2367 discussion 2367
  27. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. 2001;91:2238–2245
  28. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83:1561–1566
  29. Diamond TH, Winters J, Smith A, et al.  The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92:1444–1450
  30. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J. Clin. Endocrinol. Metab. 1993;76:288–290
  31. Smith MR, Finkelstein JS, McGovern FJ, et al.  Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 2002;87:599–603
  32. Fried LP, Tangen CM, Walston J, et al.  Frailty in older adults: evidence for a phenotype. J. Gerontol. A: Biol. Sci. Med. Sci. 2001;56:M146–M156
  33. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older [see comments]. N. Engl. J. Med. 1997;337:670–676
  34. Giovannucci E, Rimm EB, Wolk A, et al.  Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 1998;58:442–447
  35. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control. 1998;9:559–566
  36. Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control. 1998;9:567–582
  37. Smith MR, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; in press
  38. Orwoll E, Ettinger M, Weiss S, et al.  Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 2000;343:604–610
  39. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J. Clin. Endocrinol. Metab. 2001;86:5252–5255
  40. Smith EP, Boyd J, Frank GR, et al.  Oestrogen resistance caused by a mutation in the oestrogen-receptor gene in a man. N. Engl. J. Med. 1994;331:1056–1061
  41. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of oestrogens. J. Clin. Endocrinol. Metab. 1995;80:3689–3698
  42. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of oestrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 1998;339:599–603
  43. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men. Positive associations with serum oestrogens and negative associations with androgens. J. Clin. Invest. 1997;100:1755–1759
  44. Khosla S, Melton III LJ, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable oestrogen. J. Clin. Endocrinol. Metab. 1998;83:2266–2274
  45. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J. Bone Miner. Res. 1997;12:1833–1843
  46. Barrett-Connor E, Mueller JE, von Muhlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of oestradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 2000;85:219–223
  47. Khosla S, Melton III LJ, Atkinson EJ, O’Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 2001;86:3555–3561
  48. Scherr D, Pitts WR, Vaughn ED. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J. Urol. 2002;167:535–538
  49. Taxel P, Fall PM, Albertsen PC, et al.  The effect of micronized oestradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J. Clin. Endocrinol. Metab. 2002;87:4907–4913
  50. Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology. 1996;47:13–25 discussion 29–32
  51. Iversen P, Tyrrell CJ, Kaisary AV, et al.  Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology. 1998;51:389–396
  52. Tyrrell CJ, Kaisary AV, Iversen P, et al.  A randomised comparison of ‘Casodex’ (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. 1998;33:447–456
  53. Boccardo F, Rubagotti A, Barichello M, et al.  Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project Study [see comments]. J. Clin. Oncol. 1999;17:2027–2038
  54. Wirth M, See W, McLeod D, Iversen P, Persson B, Carroll K. Bicalutamide (Casodex) 150mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. 2001;20: Abstract 705
  55. Verhelst J, Denis L, Van Vliet P, et al.  Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin. Endocrinol. (Oxf). 1994;41:525–530
  56. Smith M, Fallon M, Goode M. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003; in press
  57. Sieber PR, Keliier DL, Kahnoski RJ, Garcia-Vargas JE, Gallo J, McFadden S. Bone mineral density is maintained during bicalutamide (‘Casodex’) treatment. Proc. Am. Soc. Clin. Oncol. 2002;21:196a

PII: S0305-7372(03)00076-8

doi: 10.1016/S0305-7372(03)00076-8

Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 211-218 , June 2003

Article Tools